Provided by Tiger Fintech (Singapore) Pte. Ltd.

Marker Therapeutics, Inc.

1.27
+0.10008.55%
Post-market: 1.270.00000.00%18:28 EDT
Volume:50.64K
Turnover:62.88K
Market Cap:13.60M
PE:-1.06
High:1.28
Open:1.21
Low:1.16
Close:1.17
Loading ...

Marker Therapeutics Inc - Mt-601 Well Tolerated With No Icans Observed

THOMSON REUTERS
·
19 Dec 2024

BRIEF-Marker Therapeutics Awarded $9.5 Mln Grant From The Cancer Prevention & Research Institute Of Texas (Cprit)

Reuters
·
17 Dec 2024

Marker Therapeutics awarded $9.5M grant from CPRIT

TIPRANKS
·
17 Dec 2024

Marker Therapeutics: Plans to Investigate Its Potential Application Beyond Lymphoma in Patients With Solid Tumors

THOMSON REUTERS
·
17 Dec 2024

Marker Therapeutics Awarded $9.5 Million Grant From the Cancer Prevention & Research Institute of Texas (Cprit) to Support the Investigation of Mt-601 in Patients With Pancreatic Cancer

THOMSON REUTERS
·
17 Dec 2024

Marker Therapeutics Inc: Anticipates Clinical Program Initiation in 2025

THOMSON REUTERS
·
17 Dec 2024

Press Release: Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dow Jones
·
17 Dec 2024

Marker Therapeutics Leads 3 Noteworthy US Penny Stocks

Simply Wall St.
·
06 Dec 2024

BRIEF-Marker Therapeutics Files For Mixed Shelf Of Up To $300 Million

Reuters
·
28 Nov 2024

Marker Therapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
28 Nov 2024

Marker Therapeutics Inc Files for Mixed Shelf of up to $300 Mln – SEC Filing

THOMSON REUTERS
·
28 Nov 2024

Marker Therapeutics Advances in Clinical Trials and Finances

TIPRANKS
·
15 Nov 2024

Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate

Benzinga
·
15 Nov 2024

Marker Therapeutics Q3 EPS USD -0.26

THOMSON REUTERS
·
15 Nov 2024